Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...
The healthcare industry has a growing need for real world evidence (RWE) and the capture of holistic longitudinal outcomes. This evolution is a result of payers, providers, regulators, and patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback